State Street Corporation has disclosed a significant investment in 4D Molecular Therapeutics, Inc., acquiring 4.5% of the company’s common stock. This investment, reported in a recent Schedule 13G filing, highlights State Street's confidence in the biotech sector, particularly within the biological products industry.
4D Molecular Therapeutics, based in Emeryville, California, focuses on developing innovative gene therapies. The company operates in the biological products sector, specifically under the SIC code 2836, which encompasses biological products excluding diagnostic substances. This strategic investment comes as 4D Molecular Therapeutics continues to advance its research and development efforts.
According to the filing dated November 10, 2026, State Street Corporation beneficially owns 2,469,425 shares of 4D Molecular Therapeutics, with shared voting power over 2,416,070 shares. The filing states, "The securities referred to above were acquired and are held in the ordinary course of business." This indicates that State Street's investment is not intended to influence the control of 4D Molecular Therapeutics but rather reflects a belief in the company’s potential.
This investment may impact various stakeholders, including existing shareholders and competitors in the biotech industry. As 4D Molecular Therapeutics continues to grow, it may face increased competition from other companies in the biological products sector. The filing also notes that State Street's investment is part of its broader portfolio strategy, which may include other firms in the biotech space.
Looking ahead, 4D Molecular Therapeutics is expected to continue its focus on developing groundbreaking therapies. The filing does not indicate any immediate next steps regarding corporate governance or future filings related to this investment.
Read Next
Sven-Olof Lindblad sells shares in Lindblad Expeditions
Zeo Energy CEO Timothy Bridgewater Acquires 107,955 Shares
Manthripragada Vijay Acquires Additional Shares in Onterris
Laws James Acquires Shares in Onterris, Inc. via RSUs
Eightco Holdings CEO Acquires 100,000 Shares of Stock
Eightco CFO Vroman Acquires 15,000 Shares in Stock Transaction





